Please complete this form and list your purchase and sale transaction(s) for NewLink Genetics Corporation (NASDAQ: NLNK) between September 17, 2013 and May 9, 2016, inclusive (the “Class Period”):
You may also contact Jon Naji, Esq. at 484-270-1453, or you may submit your information via email at firstname.lastname@example.org, or you may click here to print a PDF of this form.
On May 12, 2016, the initial complaint in this securities class action was filed against NewLink Genetics Corporation (“NewLink” or the “Company”), and certain of NewLink’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act. The Complaint alleges that throughout the class period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s algenpantucel-L treatment was ineffective and potentially harmful to patients; and (ii) as a result of the foregoing, NewLink’s public statements were materially false and misleading at all relevant times.
Current Status of Case:
Defendants filed a Motion to Dismiss the second amended complaint (the “Amended Complaint”) on July 31, 2018. On February 13, 2019, the Court issued an Order granting Defendants' Motion to Dismiss the Amended Complaint. Lead Plaintiffs filed a Notice appealing the dismissal on March 14, 2019. On July 13, 2020, the Court of Appeals affirmed in part and reversed in part the District Court's dismissal Order. The case was remanded back to the District Court for further proceedings. On April 2, 2021, the District Court issued an Order preliminarily approving Settlement and entered a Final Judgment on September 22, 2021. This action has concluded.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at email@example.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.